Prostacaid induces G2/M cell cycle arrest and apoptosis in human and mouse androgen-dependent and-independent prostate cancer cells

Integrative Cancer Therapies

Volumn 9, Issue 2, 2010, Pages 186-196

  Yan, Jun ^a   Katz, Aaron E ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

AKT signal pathway; apoptosis; cell cycle arrest; herbal medicine; MAPK signal pathway; prostate cancer

Indexed keywords

ANDROGEN; BIM PROTEIN; CASPASE 3; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; HERBACEOUS AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTACAID; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; PROTEIN S6; UNCLASSIFIED DRUG; MINERAL; PLANT EXTRACT; VITAMIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN LNCAP; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME; ANIMAL; CELL DIVISION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANDROGENS; ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MALE; MICE; MINERALS; MITOGEN-ACTIVATED PROTEIN KINASES; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TIME FACTORS; VITAMINS;

EID: 77954195981     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410371478     Document Type: Article

References (41)

1. Petrylak DP The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology. 2005; 65 (suppl 5). 3-7.
2. Zimmerman RA, Thompson IM Jr. Prevalence of complementary medicine in urologic practice: a review of recent studies with emphasis on use among prostate cancer patients. Urol Clin North Am. 2002; 29: 1-9.
3. Lee DH, Szczepanski M., Lee YJ Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. Biochem Pharmacol. 2008; 75: 2345-2355.
4. Wang TT, Hudson TS, Wang TC, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis. 2008; 29: 2001-2010.
5. Lee SC, Chan WK, Lee TW, et al. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Nutr Cancer. 2008; 60: 483-491.
6. Bell C., Hawthorne S. Ellagic acid, pomegranate and prostate cancer: a min review. J Pharm Pharmacol. 2008; 60: 139-144.
7. Shenouda NS, Zhou C., Browning JD, et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer. 2004; 49: 200-208.
8. Sliva D., Jedinak A., Kawasaki J., Harvey K., Slivova V. Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling. Br J Cancer. 2008; 98: 1348-1356.
9. Zhu T., Guo J., Collins L., et al. Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells. Br J Cancer. 2007; 96: 583-590.
10. Stanley G., Harvey K., Slivova V., Jiang J., Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem Biophys Res Commun. 2005; 330: 46-52.
11. Sliva D. Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther. 2003; 2: 358-364.
12. Kobayashi H., Matsunaga K., Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev. 1995; 4: 275-281.
13. Hsieh TC, Wu JM Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells. Int J Oncol. 2001; 18: 81-88.
14. Wang S., Gao J., Lei Q., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003; 4: 209-221.
15. Trotman LC, Niki M., Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1: E59.
16. Gao H., Ouyang X., Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A. 2006; 103: 14477-14482.
17. Kinkade CW, Castillo-Martin M., Puzio-Kuter A., et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008; 118: 3051-3064.
18. Gao H., Ouyang X., Banach-Petrosky W., et al. A critical role of p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A. 2004; 101: 17204-17209.
19. Sharrard RM, Maitland NJ Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br J Cancer. 2000; 83: 1102-1109.
20. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998; 58: 2720-2723.
21. Davies MA, Kim SJ, Parikh NU, Dong Z., Bucana CD, Gallick GE Adenoviral-mediated expression of MMAC/ PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res. 2002; 8: 1904-1914.
22. Vijayabalu MR, Kamagaraj P., Arunkumar A., Ilangovan R., Aruldhas MM, Arunakaran J. Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol. 2005; 131: 765-771.
23. Xing N., Chen Y., Mitchell SH, Young CY Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001; 22: 409-414.
24. Nachshon-Kedmi M., Yannai S., Fares FA Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3′2-diindolylmethan through the mitochondrial pathway. Br J Cancer. 2004; 91: 1358-1363.
25. Bhuiyan MM, Li Y., Banerjee S., et al. Down-regulation of androgen receptor by 3,3′2-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res. 2006; 66: 10064-10072.
26. Kong D., Li Y., Wang Z., Banerjee S., Sarkar FH Inhibition of angiogenesis and invasion by 3,3′2-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007; 67: 3310-3319.
27. Ahmad A., Kong D., Sarkar SH, Wang Z., Banerjee S., Sarkar FH Inactivation of uPA and its receptor uPAR by 3,3′2-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem. 2009; 107: 516-527.
28. Rahman KM, Banerjee S., Ali S., et al. 3,3′2-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through surviving down-regulation. Cancer Res. 2009; 69: 4468-4475.
29. Aziz MH, Nihal M., Fu VX, Jarrard DF, Ahmad N. Resveratrol-caused apoptosis o fhuman prostate carcinoma LNCaP cells is mediated via modulation of phosphotidylinositol 3′2-kinasse/ Akt pathway and Bcl-2 family proteins. Mol Cancer Ther. 2006; 5: 1335-1341.
30. Hsieh TC, Wu JM Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res. 2009; 29: 4025-4032.
31. Cruz-Correa M., Shoskes DA, Sanchez P., Zhao R., Hylind LM, Wexner SD Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006; 4: 1035-1038.
32. Cully M., You H., Levine AJ, Mak TW Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006; 6: 184-192.
33. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J., Spurr NK Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 1995; 55: 4800-4803.
34. Komiya A., Suzuki H., Ueda T., et al. Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer. 1996; 17: 245-253.
35. Dal Col J., Dolcetti R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle. 2008; 7: 2813-2816.
36. Asnaghi L., Calastretti A., Bevilacqua A., et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene. 2004; 23: 5781-5791.
37. Jin YP, Fishbein MC, Said JW, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol. 2004; 65: 291-302.
38. Ewings KE, Wiggins CM, Cook SJ Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle. 2007; 6: 2236-2240.
39. Solomon MJ, Lee T., Kirschner MW Role of phosphorylation in p34cdc2 activation: identification of an activating kinase. Mol Biol Cell. 1992; 3: 13-27.
40. Schwartz GK, Shah MA Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005; 23: 9408-9421.
41. Antony B., Merina B., Iyer VS, Judy N., Lennertz K., Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95′ CG (BiocurcumaxTM), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008; 70: 445-449.